Preferences and Acceptability for Long-Acting PrEP Agents Among Pregnant and Postpartum Women with Experience Using Daily Oral PrEP in South Africa and Kenya

Authors: Nafisa J. Wara^{1§}, Rufaro Mvududu², Mary M. Marwa³, Laurén Gómez⁴, Nyiko Mashele², Catherine Orrell⁵, Corrina Moucheraud⁶, John Kinuthia^{3,4}, Grace John-Stewart^{4,7,8,9}, Landon Myer², Risa Hoffman¹⁰, Jillian Pintye^{4,11}, Dvora L. Joseph Davey^{2,10,12}

Affiliations:

¹David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA ²Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa

⁵Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and the Department of Medicine, University of Cape Town, South Africa

⁶Department of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA

⁷Department of Epidemiology, University of Washington, Seattle, Washington, USA

Correspondence:

Nafisa Wara

Email: nwara@mednet.ucla.edu
Telephone: 518-577-3170

Address: 10833 Le Conte Ave, Los Angeles CA 90095

Keywords: PrEP, long-acting, pregnancy, breastfeeding, South Africa, Kenya

Email addresses of authors:

NJW: nwara@mednet.ucla.edu RM: rufaro.mvududu@uct.ac.za MMM: mmarwa@uw.edu LG: gomezl4@uw.edu

NM: nyiko.mashele@uct.ac.za

CO: Catherine.orrell@hiv-research.org.za

CM: cmoucheraud@g.ucla.edu

JK: kinuthia@uw.edu GJ-S: gjohn@uw.edu

LM: landon.myer@uct.ac.za RH: rhoffman@mednet.ucla.edu

JP: jpintye@uw.edu

DLID: dvora.josephdavey@uct.ac.za

³Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya

⁴Department of Global Health, University of Washington, Seattle, Washington, USA

⁸Department of Medicine, University of Washington, Seattle, Washington, USA

⁹Department of Pediatrics, University of Washington, Seattle, Washington, USA

¹⁰Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA

¹¹Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, Washington, USA

¹²Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA

4

5

6

7

8 9

10

11

12 13

14

15

16 17

18

19

20

21

22

23

24

25

26 27

28 29

30

31

Abstract Introduction: Long-acting pre-exposure prophylaxis (PrEP) options could overcome some barriers to oral PrEP persistence during pregnancy and postpartum. We evaluated long-acting PrEP preferences among oral PrEP-experienced pregnant and postpartum women in South Africa and Kenya, two countries with high coverage of oral PrEP and with pending regulatory approvals for long-acting injectable cabotegravir and the dapivirine vaginal ring (approved in South Africa, under review in Kenya). Methods: From September 2021 to February 2022, we surveyed pregnant and postpartum women enrolled in oral PrEP studies in South Africa and Kenya. We evaluated oral PrEP attitudes and preferences for existing and future long-acting PrEP methods. Results: We surveyed 190 women in South Africa (67% postpartum; median age 27 years [IQR 22-32]) and 204 women in Kenya (79% postpartum; median age 29 years [IQR 25-33]). 75% of participants reported oral PrEP use within the last 30 days. Overall, 49% of participants reported negative oral PrEP attributes, including side effects (21% South Africa, 30% Kenya) and pill burden (20% South Africa, 25% Kenya). Preferred PrEP attributes included long-acting method, effectiveness, safety while pregnant and breastfeeding, and free medication. Most participants (75%, South Africa and Kenya) preferred a potential long-acting injectable over oral PrEP, most frequently for longer duration of effectiveness in South Africa (87% South Africa, 42% Kenya) versus discretion in Kenya (5% South Africa, 49% Kenya). 87% of participants preferred oral PrEP over a potential long-acting vaginal ring, mostly due to concern about possible discomfort with vaginal insertion (82% South Africa, 48% Kenya). Significant predictors of long-acting PrEP preference included past use of injectable contraceptive (aOR 2.48, 95% CI: 1.34, 4.57), disliking at least one oral PrEP attribute (aOR 1.72, 95% CI: 1.05, 2.80), and preferring infrequent PrEP use (aOR 1.58, 95% CI: 0.94, 2.65). **Conclusions:** Oral PrEP-experienced pregnant and postpartum women expressed a theoretical preference for long-acting injectable PrEP over other modalities, demonstrating potential acceptability among a key population who must be at the forefront of injectable PrEP rollout. Reasons for PrEP preferences differed by country, emphasizing the importance of increasing context-specific options and choice of PrEP modalities for pregnant and postpartum women.

Introduction

32

33

34

35

36

37

38

39

40

41 42

43

44

45 46

47

48 49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

HIV incidence remains high among cisgender women of reproductive age in South Africa and Kenya, including during pregnancy and postpartum[1-4]. Pregnant women without HIV are at elevated risk of acquisition due to structural and sociocultural factors (e.g., poverty, gender inequity) that may result in high-risk scenarios, including not knowing the HIV status of their partner(s), engaging in sexual activity without condoms, and having multiple sex partners[5-8]. Furthermore, the risk of vertical HIV transmission is elevated during pregnancy and breastfeeding due to acute maternal HIV infection[9,10]. A concerted effort is needed to reduce HIV infections among pregnant and breastfeeding individuals, and their infants. Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) for HIV prevention is being rapidly scaled in South Africa and Kenya, and these two countries have the highest and second highest number of PrEP initiations globally[11]. Studies have reported high rates of oral PrEP uptake among pregnant and postpartum women in South Africa and Kenya [12,13]. However, the delivery of daily oral PrEP among pregnant and postpartum women is challenged by insufficient integration of PrEP provision and counseling into existing antenatal and postpartum systems[14]. Furthermore, self-reported adherence on oral PrEP (e.g., taking PrEP daily) was low among pregnant and postpartum women in Kenya, and limited adherence was identified among pregnant and postpartum women taking oral PrEP in South Africa through dried blood spot analysis [13,15]. Substantial barriers to oral PrEP adherence exist in these populations, including pill burden, stigma and limited disclosure of PrEP use, and financial and logistical barriers to accessing a clinic for PrEP[16-18]. Strategies to overcome barriers to PrEP adherence are urgently needed. Long-acting modalities, such as injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring, may improve PrEP initiation and persistence among pregnant and postpartum women. CAB-LA, an intramuscular injection administered every eight weeks, is superior to oral PrEP, reducing risk of HIV infection by 88% compared to daily oral TDF/FTC among cisgender women in Sub-Saharan Africa[19]. Preliminary data show that CAB-LA is well tolerated during pregnancy and has a similar pharmacokinetic profile to its use by nonpregnant women[20,21]. CAB-LA received regulatory approval in the United States in December 2021 and is pending regulatory approval in South Africa, Kenya, and other countries in Southern Africa[11]. The dapivirine ring, inserted vaginally and replaced every four weeks, has been shown to reduce the risk of HIV infection by approximately 30% and is not associated with adverse pregnancy or infant outcomes[22]. The dapivirine ring received regulatory approval in South Africa in March 2022, and is pending approval in Kenya[11]. These developments highlight the urgent need to understand potential facilitators and barriers to uptake and persistence on these novel PrEP methods among pregnant and

65

66

67

68

69 70

71

72

73 74

75

76

77

78

79

80

81

82

83

84 85

86

87

88

89

90

91

92

93

94

postpartum women. Our study aims to assess preferences for and perceptions of long-acting PrEP methods among oral PrEP-experienced pregnant and postpartum women in Kenya and South Africa. Methods Study participants: We conducted surveys with participants enrolled in an observational cohort study assessing daily oral PrEP initiation and persistence among pregnant and breastfeeding women (PBFW) in Cape Town, South Africa (PrEP-PP) and an observational extension cohort of a cluster randomized trial offering daily oral PrEP among PBFW in Western Kenya (PrIMA-X)[23,24]. Eligibility criteria for PrEP-PP included: ≥16 years old, confirmed HIV-negative serostatus by a 4th generation antigen/antibody combination HIV test (Abbott), intention to stay in Cape Town through the postpartum period, and no contraindications to PrEP use. Eligibility criteria for PrIMA-X included: ≥15 years old, confirmed HIV and TB negative, intention to reside in the area for at least one year postpartum, and plans to receive postnatal and infant care at the study facility. Enrolment criteria for this subsample included: currently using or having previously used daily oral PrEP; currently pregnant or ≤9 months postpartum; and enrolment in PrEP-PP or PrIMA-X. Data collection: Between September 2021 and February 2022, trained study staff fluent in English and either isiXhosa, Kiswahili, or Luo approached women attending PrEP-PP or PrIMA-X follow-up visits to introduce the study. Study staff then screened participants for study eligibility, obtained written informed consent in English or the participant's local language (isiXhosa, Kiswahili, or Luo), and administered the survey to eligible consenting participants. Study staff asked participants survey questions and recorded responses on a tablet. The survey took 30-40 minutes and was completed on REDCap, a secure web-based platform[25]. Participants received 120 Rand in South Africa (~\$7 USD) or KSh 300 in Kenya (~\$3 USD) for their participation in the study as well as transportation expenses. Survey Measures: Participant Sociodemographic Characteristics We collected (a) basic demographic data (including age, obstetric history, education level, employment, number of sexual partners), (b) HIV risk perception (response to "How would you describe your chances of getting HIV in the next year?" from "no chance at all" to "great chance"), (c) current alcohol use adapted from the Alcohol Use Disorders Identification Test[26,27], (d) PrEP adherence based on 30-day recall (i.e.

responding "yes" or "no" to taking PrEP within the past 30 days), (e) clinic access (including transportation method, total travel time, and total transportation cost), and (f) previous use of any contraceptive methods. We also assessed PrEP stigma using a seven-item scale derived from existing literature in which participants responded to statements describing experiences of PrEP stigma via a 5-point Likert scale ranging 0 = "strongly disagree" to 4 = "strongly agree" [28,29]. Current and Future PrEP Preferences We assessed perceptions of daily oral PrEP by asking participants what they like and dislike about oral PrEP. We described methods of long-acting HIV prevention currently pending regulatory approval or in development, and asked participants about preferences regarding HIV prevention modalities that may be available in the future. We adapted a list of PrEP characteristics from a discrete choice experiment of HIV prevention methods assessed within the Quatro Study[30]. We asked participants to rank the top three most important characteristics of a potential HIV prevention product, the top three most important accessrelated characteristics, and how frequently they would theoretically use an HIV prevention method. Long-acting PrEP Preferences We assessed preferences regarding injectable PrEP and the vaginal ring by asking participants whether they would prefer to switch to the long-acting method or remain on oral PrEP. We then assessed reasons for preferring the long-acting method or oral PrEP. Statistical analyses: We used descriptive statistics (median, interquartile range [IQR], frequency) to report participant responses, and used Chi-square, Fischer's Exact, and Wilcoxon rank sum to compare responses between countries. We used univariate and multivariable logistic regression models to assess predictors of preferring a long-acting PrEP method (injection or ring) over oral PrEP (among those with this preference). We adjusted for a priori potential confounders (maternal age and country) in the multivariable models. Statistical analyses were conducted with STATA v.17[31]. Ethics: The PrEP-PP study was approved by the Human Research Ethics Committee of the University of Cape Town Faculty of Health Sciences (#297/2018) and by the University of California, Los Angeles Institutional Review Board (IRB#18-001622). The PrIMA-X study was approved by the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (P73/02/2017) and by the University of Washington Human Subjects Division (STUDY00000438).

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

127

128

129

130

131

132

133134

135136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

Results Overall, 394 women were enrolled in the study, 190 women from the South African cohort and 204 from the Kenyan cohort. Median ages were 27 (IQR=22-32) and 29 (IQR=25-33) respectively (Table 1). Overall, 33% of South African participants were pregnant (n=63) while 21% of Kenyan participants were pregnant (n=42), with the remaining in both groups postpartum. Most participants completed some or all secondary school education (total n=326, 83%) although secondary education was more common in South Africa (93%, Kenya 74%, p<0.01). Unemployment was more common in Kenya (Kenya 87%, South Africa 72%, p<0.01). Almost all (95%) women reported having at least one current sexual partner (n=373). Most participants reported that they took at least one dose of PrEP over the previous 30 days at the time of the survey (South Africa 82%, Kenya 68%, p<0.001), and median time on PrEP among current PrEP users was 337 days (IQR=263-420) and 308 days (IQR=114-442) among South African and Kenyan participants, respectively. At entry into the parent study, 52% of South African women and 81% of Kenyan women reported any perceived risk of HIV acquisition (p<0.01). More than half endorsed no forms of PrEP stigma (66%, n=251/380), although more women in Kenya endorsed at least one form of PrEP stigma (Kenya 40%, South Africa 27%, p=0.01). At the time of the survey, participants' median travel time to and from the clinic was 30 minutes (IQR=20-40) in South Africa and 55 minutes (IQR=31-60) in Kenya (p<0.01), and median cost to travel to and from the clinic was USD \$1.32 (IQR=1.32-1.32) and \$1.75 (IQR=0.88-2.64) respectively (p=0.01. When asked about any previous experience with contraceptives, women frequently described use of injectable contraceptives (South Africa 94% vs Kenya 66%, p<0.01), followed in South Africa by use of male condoms (n=171, 90%) and contraceptive implants (n=70, 37%). Among women in Kenya, injectable contraceptive was most common (n=134, 66%), followed by the contraceptive implant (n=111, 54%) and then male condoms (n=46, 23%). **Experiences with Oral PrEP** Almost all participants (n=386, 98%) reported efficacy in HIV prevention as a positive characteristic of daily oral PrEP, followed by daily oral PrEP having few or no side effects (n=61, 15%) and being easy to use (n=27, 7%) (Table 2). In addition, 10 (5%) participants in Kenya (compared to none in South Africa) liked that oral PrEP was discreet and 5 (2%) participants in South Africa (compared to none in Kenya) reported oral PrEP's safety during breastfeeding as a positive characteristic. Forty-two percent of women in South Africa (n=79) and 56% in Kenya (n=114, p<0.01) disliked at least one attribute about daily oral PrEP. The

most frequently reported dislikes included side effects (South Africa 21%, Kenya 30%, p=0.03), daily use (South Africa 20%, Kenya 25%, p=0.20), and taking it orally (South Africa 6%, Kenya 11%, p=0.08).

Future PrEP Preferences

When asked to rank characteristics of a potential PrEP product that may be available to them in the future, 52% of participants (n=203) ranked effectiveness at preventing HIV as the most important, followed by the ability to have a healthy pregnancy (n=47, 12%), frequency of use (n=39, 10%), tolerability (n=39, 10%), and the ability to breastfeed and have a healthy baby (n=26, 7%). However, there were country-specific differences in the ranking of several attributes: more women in Kenya ranked HIV prevention highest (78%, South Africa 23%, p<0.01), more women in South Africa ranked having a healthy pregnancy (19%, Kenya 5%, p<0.01), frequency of use (18%, Kenya 2%, p<0.01), side effects (16%, Kenya 4%, p<0.01), and privacy (6%, Kenya 1%, p=0.01) as most important (**Table 3**). When asked to rank access-related characteristics of a potential PrEP product, 52% of participants ranked medication being free as the most important, followed by ease of the process by which the product is obtained, location, and total time it takes to get the product. When asked to rank preferred frequency of PrEP use, participants most frequently preferred once a year (n=123, 31%), followed by once per month (n=62, 16%), once every 2-3 months (n=59, 15%), before sex (n=53, 13%), every day (n=46, 12%), once every 6 months (n=45, 11%), and after sex (n=6, 2%). Kenyan women preferred PrEP use once every 6 months, or once every 2-3 months, whereas South African women preferred a product that could be used once a year (p<0.01).

Preference of long-acting PrEP modalities

Overall, three-fourths of participants (n=297, South Africa 74%, Kenya 76%, p=0.60) responded that they would prefer to switch to injectable PrEP over remaining on oral PrEP if it were available (**Figure 1**). South African and Kenyan women differed in their reasons for preferring injectable PrEP over oral PrEP: participants in South Africa more commonly preferred it for its longer duration of effectiveness (South Africa 87%, Kenya 42%, p<0.01) and not having to take a daily pill (South Africa 57%, Kenya 41%, p<0.01), while participants in Kenya were more likely to state reasons of privacy (Kenya 49%, South Africa 5%, p<0.01) and not having to carry pills (Kenya 42%, South Africa 13%, p<0.01) (**Supplementary Table 1**). The most common concerns regarding injectable PrEP were injection pain and potential side effects. Although overall these concerns were not frequently reported, Kenyan participants were more concerned than South African participants regarding the safety of the new injectable (Kenya 13%, South Africa 4%, p=0.01) and its safety for infants if using the injectable while breastfeeding (Kenya 6%, South Africa 0%, p=0.01).

Fewer women (n=40, 10%) would prefer switching to the vaginal ring over oral PrEP in both South Africa and Kenya (12% and 9% respectively). South African women were interested in the vaginal ring most frequently due to its longer duration (n=14/22, 64%) and not having to remember to take a daily pill (n=12/22, 55%), while most common reasons for preferring the vaginal ring in Kenya were because it was "easy to use" (n=8/18, 44%) or did not involve carrying pills (n=6/18, 33%). Participants were unsure or preferred oral PrEP over the vaginal ring most frequently due to its insertion into the vagina particularly among South African women (South Africa 82%, Kenya 48%, p<0.01), potential side effects more so among Kenyan women (South Africa 21%, Kenya 33%, p=0.02), and concerns about safety (South Africa 23%, Kenya 27%). Participants in South Africa were also more frequently concerned about the vaginal ring not providing sufficient protection against HIV (14%, Kenya 7%, p=0.03). In multivariable analyses adjusting for age and country, preference of a long-acting PrEP method (either injectable PrEP or vaginal ring) over daily oral PrEP was associated with prior use of injectable contraception (aOR=2.48, 95% CI=1.34, 4.57), disliking at least one attribute of daily oral PrEP (aOR=1.72, 95% CI=1.05, 2.80), disliking the daily use of oral PrEP (aOR=1.92, 95% CI=1.01, 3.67), and preferring longer duration of effectiveness (aOR=1.58, 95% CI=0.94, 2.65) (Table 4). Preferring a long-acting PrEP method over oral PrEP was negatively associated with previous use of the female condom (aOR=0.27, 95% CI=0.07, 1.12) and liking taking oral PrEP daily (aOR 0.30, 95% CI=0.07, 1.24).

Discussion

We identified a strong theoretical preference for long-acting injectable PrEP among pregnant and postpartum women in Kenya and South Africa. Additionally, about one-half of women reported liking daily oral PrEP, indicating the importance of providing pregnant and postpartum women with choices of modalities. Studies assessing end-user preference among African women of potential HIV prevention methods (multiple vaginally inserted methods, injection, pill) showed that women had varied preference for these HIV prevention modalities, and women described the importance of personal preference in product choice[32-34]. Similar to HIV prevention, studies on contraceptive choice indicate that the best method for an individual depends on their preferences, necessitating a diversity of contraceptive options[35-37]. Our data suggest that the availability of choices to meet personal preferences is essential to improving overall uptake of HIV prevention methods among pregnant and postpartum women as well. Furthermore, women in South Africa and Kenya did not differ in preferences for long-acting PrEP modalities compared to oral PrEP, but did differ in the reasoning behind their preferences, indicating the importance of context-specific implementation when providing HIV prevention modalities.

Sociodemographic characteristics and available PrEP modalities differ between countries, indicating that

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

differences between countries in PrEP preferences among pregnant and postpartum women need to be studied and incorporated into country-specific plans for PrEP rollout. Our findings on preference for long-acting injectable PrEP among pregnant and postpartum women, as well as most reasons for their PrEP preferences, align with the existing literature among nonpregnant women. Women also noted need for safety data in pregnancy and lactation in our study, which was distinct for this population. In studies providing hypothetical choices between long-acting PrEP modalities, nonpregnant women from Kenya and South Africa preferred injectable methods of HIV prevention over other modalities, despite similar concerns regarding injection pain[38-40]. In studies assessing acceptability of long-acting injectable PrEP among women within clinical trials in Africa and the United States, participants described acceptability of long-acting injectable PrEP due to its ease of use and long-term protection and would use the method again[41-43], which may suggest that hypothetical acceptability of long-acting injectable PrEP among pregnant and postpartum women may align with its acceptability among nonpregnant women during implementation. Some PrEP preferences identified by women in our study were specific to the pregnancy-postpartum period, such as the importance of safety in pregnancy and infant safety while breastfeeding on PrEP. Previous data have identified the positive impacts of counseling about infant safety on oral PrEP initiation among women in Kenya, highlighting that obtaining further data on pregnancy outcomes and infant safety of CAB-LA, as well as counseling on safety may be beneficial for uptake[18]. Pregnant and postpartum women in our study reported that they would prefer to use a long-acting injectable PrEP for privacy and discreetness of this method, highlighting the role of long-acting PrEP to mitigate sociocultural barriers previously identified with oral PrEP use[16-18,44]. Qualitative studies in Kenya and South Africa have described the negative community perception surrounding PrEP use experienced by pregnant and nonpregnant women, particularly due to its association with high-risk sexual behavior as well as being conflated with antiretroviral therapy, leading to concealment of product use[45-47]. A qualitative study assessing oral PrEP perceptions among pregnant and postpartum women in Kenya additionally described fear of male partners becoming violent if discovering their PrEP use, indicating that stigma and negative sentiments towards PrEP within a household may decrease PrEP disclosure and necessitate concealment[48,49]. The availability of a HIV prevention method, such as long-acting injectable PrEP, that does not require daily administration or concealment of physical pills may make it easier for pregnant and postpartum women experiencing PrEP stigma to persist on the HIV prevention method – and has been hypothetically posed by women as a potential solution in previous qualitative work[47]. Longacting PrEP modalities must be made available in conjunction to other solutions that mitigate community-

and individual-level stigma experienced by women in Kenya and South Africa, such as community-facing

interventions involving media and educational initiatives, as well as the involving of male partners in HIV prevention and education [41,50]. Few pregnant and postpartum women reported preference for the PrEP vaginal ring over oral PrEP, which may be due to unfamiliarity with the method as well as its lower efficacy. Existing acceptability and demonstration studies of the dapivirine ring for HIV prevention show that despite similar initial concerns regarding insertion into the vagina and potential side effects, women in Sub-Saharan Africa who began using vaginal rings for HIV prevention developed familiarity with the method, found it easy to integrate into their lives, and reported willingness to use the method in the future [51-54]. Our data in the context of these studies indicate the importance of education regarding vaginal ring insertion and anticipated side effects when counseling about available HIV prevention modalities, and reemphasize the need for available choice in HIV prevention methods that can be used individually or in combination. Prior use of injectable contraception was associated with a preference for injectable PrEP, indicating that contraceptive knowledge and familiarity with the concept of regular injections as a prevention measure may impact uptake of injectable PrEP among pregnant and postpartum women. Studies assessing acceptability of multipurpose prevention technologies combining HIV and pregnancy prevention similarly showed that injections were preferred compared to a ring or pill-form of combination prevention, and that past experience with similar contraceptive delivery forms was a significant predictor of their method choice[55-57]. Combining HIV prevention education with family planning education may improve uptake of HIV prevention, due to existing familiarity with long-acting contraceptive modalities. Further, the future development of combination prevention methods may improve uptake of HIV prevention. Limitations Our study included pregnant and postpartum women with knowledge and experience with oral PrEP. As such, our results may differ from preferences of pregnant and postpartum women without prior experience using PrEP. Our surveys provided a hypothetical choice between PrEP modalities, as some methods are not yet available in South Africa and Kenya (i.e. injectable PrEP in both countries, vaginal ring PrEP in Kenya). Responses may differ from PrEP choices during an implementation offering multiple modalities. Our results may not be generalizable to other settings beyond urban South Africa and Kenya, so further study is necessary on the acceptability of long-acting PrEP among pregnant and postpartum women in other settings.

Conclusions

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

288

289

290

291

292

293

294

295296

297

298299

300

301

302

303

304

305

306

307308

309

310

311

312313

314

315

316

317

318

319

Our study demonstrates that pregnant and postpartum women on oral PrEP may desire a switch to longacting injectable PrEP as it becomes available in South Africa and Kenya. Women in our study had different PrEP preferences and different reasons for these preferences, indicating the need for client-centered PrEP programs that offer diverse choices for HIV prevention and empower women to make the choice best suited to their needs and lifestyle. Some of these preferences, such as safety for maternal-infant dyad, were specific to the pregnant-postpartum period, while others likely reflected general preferences of women about PrEP. Overall, further efforts are needed to increase choice and accessibility of various PrEP options to benefit the well-being of pregnant and postpartum women and their infants. **Conflict of Interest Statement** The PrEP-PP study received the study drug (Truvada®) from Gilead Sciences (Foster City, CA, USA). Authorship Study was conceived by NJW and designed by NJW, RH, JP, DLJD. NJW oversaw study implementation and data collection, analyzed the data, wrote the first draft of manuscript, and reviewed the manuscript following revision by all co-authors. RM, MM, LG, and NM reviewed the study design, oversaw study implementation and data collection, and assisted with data analysis. CO, CM, RH, JP, and DLJD reviewed the study design, study data, and data analysis. JK, GJ-S, and JP designed the PrIMA-X study, and LM and DLJD designed the PrEP-PP study. All authors contributed to the development of this manuscript, and have read and approved the final manuscript. **Acknowledgments** We would like to thank all PrEP-PP and PrIMA-X study participants for their time and perspectives, as well as the PrEP-PP and PrIMA-X project staff, the City of Cape Town Department of Health, Kenyan Ministry of Health, and Siaya and Homa Bay County Governments. **Funding** This work was funded by the National Institute of Mental Health: R01MH116771 (DJD, LM), The Eunice Kennedy Shriver National Institute of Child Health and Human Development: 1R01HD106821 (DJD) R01HD100201 (JP), the Fogarty International Center: K01TW011187 (DJD), the National Institute of Nursing Research: R01NR019220 (JP and JK) and the National Institutes of Allergy and Infectious Diseases: R01Al125498 (GJS). The PrEP-PP study received the study drug (Truvada®) from Gilead Sciences (Foster City, CA, USA).

References

- 1. UNAIDS. (n.d.). Start Free Stay Free AIDS Free 2020 Progress Report. https://www.unaids.org/sites/default/files/media_asset/start-free-stay-free-aids-free-2020-progress-report_en.pdf
- 2. Woldesenbet, S., Kufa-Chakezha, T., Lombard, C., Manda, S., Cheyip, M., Ayalew, K., Chirombo, B., Barron, P., Diallo, K., Parekh, B., & Puren, A. (2021). Recent HIV infection among pregnant women in the 2017 antenatal sentinel crosssectional survey, South Africa: Assay-based incidence measurement. PloS One, 16(4), e0249953. https://doi.org/10.1371/journal.pone.0249953
- 3. le Roux, S. M., Abrams, E. J., Nguyen, K. K., & Myer, L. (2019). HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. AIDS (London, England), 33(8), 1399–1401. https://doi.org/10.1097/QAD.000000000002224
- 4. Sirengo, M., Muthoni, L., Kellogg, T. A., Kim, A. A., Katana, A., Mwanyumba, S., Kimanga, D. O., Maina, W. K., Muraguri, N., Elly, B., Rutherford, G. W., & KAIS Study Group. (2014). Mother-to-child transmission of HIV in Kenya: results from a nationally representative study. *Journal of Acquired Immune Deficiency Syndromes* (1999), 66 Suppl 1, S66-74. https://doi.org/10.1097/QAI.000000000000115
- 5. Kharsany, A. B., Frohlich, J. A., Yende-Zuma, N., Mahlase, G., Samsunder, N., Dellar, R. C., Zuma-Mkhonza, M., Karim, S. S. A., & Karim, Q. A. (2015). Trends in HIV prevalence in pregnant women in rural South Africa. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 70(3), 289–295. https://doi.org/10.1097/QAI.0000000000000001
- Pettifor, A. E., Rees, H. V., Kleinschmidt, I., Steffenson, A. E., MacPhail, C., Hlongwa-Madikizela, L., Vermaak, K., & Padian, N. S. (2005). Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. *AIDS (London, England)*, 19(14), 1525–1534. https://doi.org/10.1097/01.aids.0000183129.16830.06
- 7. Ryan, J. H., Young, A., Musara, P., Reddy, K., Macagna, N., Guma, V., Seyama, L., Piper, J., van der Straten, A., & MTN-041/MAMMA Study Team. (2022). Sexual Attitudes, Beliefs, Practices, and HIV Risk During Pregnancy and Post-delivery: A Qualitative Study in Malawi, South Africa, Uganda, and Zimbabwe. *AIDS and Behavior*, 26(3), 996–1005. https://doi.org/10.1007/s10461-021-03454-y
- 8. Varga, C. A. (2003). How gender roles influence sexual and reproductive health among South African adolescents. *Studies in Family Planning*, *34*(3), 160–172. https://doi.org/10.1111/j.1728-4465.2003.00160.x
- 9. Woldesenbet, S., Kufa-Chakezha, T., Lombard, C., Manda, S., Cheyip, M., Ayalew, K., Chirombo, B., Barron, P., Diallo, K., Parekh, B., & Puren, A. (2021). Recent HIV infection among pregnant women in the 2017 antenatal sentinel crosssectional survey, South Africa: Assay-based incidence measurement. PloS One, 16(4), e0249953. https://doi.org/10.1371/journal.pone.0249953
- 10. le Roux, S. M., Abrams, E. J., Nguyen, K. K., & Myer, L. (2019). HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. AIDS (London, England), 33(8), 1399–1401. https://doi.org/10.1097/QAD.000000000002224
- 11. AVAC: Global Advocacy for HIV Prevention. (2022). *A map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs*. PrEPWatch: The Global PrEP Tracker. https://data.prepwatch.org/
- 12. Joseph Davey, D. L., Mvududu, R., Mashele, N., Lesosky, M., Khadka, N., Bekker, L., Gorbach, P., Coates, T. J., & Myer, L. (2022). Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa. Journal of the International AIDS Society, 25(2), e25866. https://doi.org/10.1002/jia2.25866
- 13. Kinuthia, J., Pintye, J., Abuna, F., Mugwanya, K. K., Lagat, H., Onyango, D., Begnel, E., Dettinger, J., Baeten, J. M., John-Stewart, G., Aquino, A. C., Ochieng, S. J., Lipesa, A. M., Naidu, A. L., Kamau, A., Njoroge, A. W., Okeah, B. O., Makabwa, C. B., Atieno, C. C., ... Fondo, Y. F. (2020). Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. *The Lancet HIV*, 7(1), e38–e48. https://doi.org/10.1016/S2352-3018(19)30335-2

- 14. Pintye J., Davey D. L. J., Wagner A. D., et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and postpartum women in high-burden settings using an implementation science framework. *Lancet HIV*. 2020;7(8):e582-e592. doi:10.1016/S2352-3018(20)30102-8
- 15. Davey D. L. J., Nyemba D., Castillo-Mancilla J., Weisner L., Norman J., Mvududu R., Mashele N., Johnson L. F., Bekker L., Gorbach P., Coates T. J., Myer L. (2022). Objective versus self-reported adherence to daily pre-exposure prophylaxis (PrEP) among pregnant and postpartum women in South Africa. Lancet HIV. Submitted.
- Beesham, I., Dovel, K., Mashele, N., Bekker, L.-G., Gorbach, P., Coates, T. J., Myer, L., & Joseph Davey, D. L. (2022). Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa. AIDS and Behavior. https://doi.org/10.1007/s10461-022-03652-2
- 17. Beesham, I., Heffron, R., Evans, S., Baeten, J. M., Smit, J., Beksinska, M., & Mansoor, L. E. (2021). Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial. AIDS and Behavior, 25(4), 1112–1119. https://doi.org/10.1007/s10461-020-03072-0
- 18. Pintye, J., O'Malley, G., Kinuthia, J., Abuna, F., Escudero, J. N., Mugambi, M., Awuor, M., Dollah, A., Dettinger, J. C., Kohler, P., John-Stewart, G., & Beima-Sofie, K. (2021). Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. *Journal of Acquired Immune Deficiency Syndromes (1999), 86*(4), e83–e89. https://doi.org/10.1097/QAI.0000000000002587
- 19. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodi N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Erratum in: Lancet. 2022 May 7;399(10337):1778. PMID: 35378077.
- 20. Delany-Moretlwe, S., Hughes, J., Guo, X., Hanscom, B., Hendrix, C. W., Farrior, J., Berhanu, R. H., Rinehart, A. R., Ford, S. L., Rooney, J. F., Adeyeye, A., Landovitz, R. J., Cohen, M. S., Hosseinipour, M. C., & Marzinke, M. (2022, February 12). Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. CROI 2022, virtual meeting. https://www.croiconference.org/abstract/evaluation-of-cab-la-safety-and-pk-in-pregnant-women-in-the-blinded-phaseof-hptn-084/
- 21. Patel, P., Ford, S. L., Baker, M., Meyer, C., Garside, L., D'Amico, R., Van Solingen-Ristea, R., Crauwels, H., Polli, J., Seal, C., Thiagarajah, S., Birmingham, E., Spreen, W., Baugh, B., Bosse, M., & Vannappagari, V. (2021). 885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials. *Open Forum Infectious Diseases*, 8(Suppl 1), S534. https://doi.org/10.1093/ofid/ofab466.1080
- Baeten, J. M., Palanee-Phillips, T., Mgodi, N. M., Mayo, A. J., Szydlo, D. W., Ramjee, G., Gati Mirembe, B., Mhlanga, F., Hunidzarira, P., Mansoor, L. E., Siva, S., Govender, V., Makanani, B., Naidoo, L., Singh, N., Nair, G., Chinula, L., Parikh, U. M., Mellors, J. W., ... MTN-025/HOPE Study Team. (2021). Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an openlabel, extension study. The Lancet. HIV, 8(2), e87–e95. https://doi.org/10.1016/S2352-3018(20)30304-0
- 23. Dettinger, J. C., Kinuthia, J., Pintye, J., Mwongeli, N., Gómez, L., Richardson, B. A., Barnabas, R., Wagner, A. D., O'Malley, G., Baeten, J. M., & John-Stewart, G. (2019). PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial. *BMJ Open*, *9*(3), e025122. https://doi.org/10.1136/bmjopen-2018-025122
- 24. Joseph Davey, D. L., Mvududu, R., Mashele, N., Lesosky, M., Khadka, N., Bekker, L.-G., Gorbach, P., Coates, T. J., & Myer, L. (2022). Early pre-exposure prophylaxis (PrEP) initiation and continuation

- among pregnant and postpartum women in antenatal care in Cape Town, South Africa. *Journal of the International AIDS Society*, 25(2), e25866. https://doi.org/10.1002/jia2.25866
- 25. Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics*, 42(2), 377–381. https://doi.org/10.1016/j.jbi.2008.08.010
- 26. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998; 158(16): 1789-95.
- 27. Kader R, Seedat S, Koch JR, Parry CD. A preliminary investigation of the AUDIT and DUDIT in comparison to biomarkers for alcohol and drug use among HIV-infected clinic attendees in Cape Town, South Africa. *Afr J Psychiatry (Johannesbg)* 2012; **15**(5): 346-51.
- 28. Klein, H., & Washington, T. A. (2019). The Pre-Exposure Prophylaxis (PrEP) Stigma Scale: Preliminary findings from a pilot study. *International Public Health Journal*, 11(2), 185–195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034943/
- 29. Munthali, R. J., Stangl, A. L., Baron, D., Barré, I., Harvey, S., Ramskin, L., Colombini, M., Naicker, N., Kapiga, S., Delany-Moretlwe, S., & the EMPOWER study team. (2022). Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial. *AIDS and Behavior*. https://doi.org/10.1007/s10461-022-03721-6
- 30. Browne, E. N., Montgomery, E. T., Mansfield, C., Boeri, M., Mange, B., Beksinska, M., Schwartz, J. L., Clark, M. R., Doncel, G. F., Smit, J., Chirenje, Z. M., & van der Straten, A. (2020). Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. *AIDS and Behavior*, 24(5), 1443–1451. https://doi.org/10.1007/s10461-019-02715-1
- 31. StataCorp. 2021. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC.
- 32. Montgomery, E. T., Beksinska, M., Mgodi, N., Schwartz, J., Weinrib, R., Browne, E. N., Mphili, N., Musara, P., Jaggernath, M., Ju, S., Smit, J., Chirenje, Z. M., Doncel, G. F., & van der Straten, A. (2019). End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. *Journal of the International AIDS Society*, 22(5), e25283. https://doi.org/10.1002/jia2.25283
- 33. van der Straten, A., Ryan, J. H., Reddy, K., Etima, J., Taulo, F., Mutero, P., Taylor, J., Piper, J., Musara, P., & MTN-041/MAMMA Study Team. (2020). Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. *Journal of the International AIDS Society*, 23(6), e25536. https://doi.org/10.1002/jia2.25536
- 34. Shapley-Quinn, M. K., Manenzhe, K. N., Agot, K., Minnis, A. M., & van der Straten, A. (2019). "We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study. *International Journal of Women's Health*, 11, 97–107. https://doi.org/10.2147/IJWH.S185712
- 35. Chappell, C. A., Harkoo, I., Szydlo, D. W., Bunge, K. E., Singh, D., Nakabiito, C., Mhlanga, F., Kamira, B., Piper, J. M., Balkus, J. E., & Hillier, S. L. (2019). Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. *Contraception*, 100(3), 214–218. https://doi.org/10.1016/j.contraception.2019.06.006
- 36. Clark, H., RamaRao, S., Unthank, C., Machiyama, K., & Thatte, N. (2017). Family Planning Evidence Brief: Expanding Contraceptive Choice (WHO/RHR/17.14 Rev.1). World Health Organization. http://apps.who.int/iris/bitstream/handle/10665/255865/WHO-RHR-17.14-eng.pdf?sequence=1
- 37. Dehlendorf, C., Levy, K., Kelley, A., Grumbach, K., & Steinauer, J. (2013). Women's preferences for contraceptive counseling and decision making. *Contraception*, 88(2), 250–256. https://doi.org/10.1016/j.contraception.2012.10.012
- 38. Minnis, A. M., Atujuna, M., Browne, E. N., Ndwayana, S., Hartmann, M., Sindelo, S., Ngcwayi, N., Boeri, M., Mansfield, C., Bekker, L.-G., & Montgomery, E. T. (2020). Preferences for long-acting Pre-Exposure

- Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. *Journal of the International AIDS Society*, 23(6), e25528. https://doi.org/10.1002/jia2.25528
- 39. Quaife, M., Eakle, R., Cabrera Escobar, M. A., Vickerman, P., Kilbourne-Brook, M., Mvundura, M., Delany-Moretlwe, S., & Terris-Prestholt, F. (2018). Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. *Medical Decision Making: An International Journal of the Society for Medical Decision Making*, 38(1), 120–133. https://doi.org/10.1177/0272989X17729376
- 40. Shapley-Quinn, M. K., Manenzhe, K. N., Agot, K., Minnis, A. M., & van der Straten, A. (2019). "We are not the same": African women's view of multipurpose prevention products in the TRIO clinical study. *International Journal of Women's Health*, 11, 97–107. https://doi.org/10.2147/IJWH.S185712
- 41. Bekker, L. G., Li, S., Pathak, S., Tolley, E. E., Marzinke, M. A., Justman, J. E., Mgodi, N. M., Chirenje, M., Swaminathan, S., Adeyeye, A., Farrior, J., Hendrix, C. W., Piwowar-Manning, E., Richardson, P., Eshelman, S. H., Redinger, H., Williams, P., Sista, N. D., & HPTN 076 Study Team. (2020). Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. *EClinicalMedicine*, *21*, 100303. https://doi.org/10.1016/j.eclinm.2020.100303
- 42. Tolley, E. E., Li, S., Zangeneh, S. Z., Atujuna, M., Musara, P., Justman, J., Pathak, S., Bekker, L.-G., Swaminathan, S., Stanton, J., Farrior, J., & Sista, N. (2019). Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). *Journal of the International AIDS Society*, 22(10), e25408. https://doi.org/10.1002/jia2.25408
- 43. Minnis, A. M., Browne, E. N., Boeri, M., Agot, K., van der Straten, A., Ahmed, K., Weinrib, R., & Mansfield, C. (2019). Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. *Journal of Acquired Immune Deficiency Syndromes* (1999), 80(4), 394–403. https://doi.org/10.1097/QAI.000000000001945
- 44. Minnis, A. M., Krogstad, E., Shapley-Quinn, M. K., Agot, K., Ahmed, K., Danielle Wagner, L., van der Straten, A., & TRIO Study Team. (2021). Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa. *Sexual and Reproductive Health Matters*, 29(1), 1927477. https://doi.org/10.1080/26410397.2021.1927477
- 45. Escudero, J. N., Dettinger, J. C., Pintye, J., Kinuthia, J., Lagat, H., Abuna, F., Kohler, P., Baeten, J. M., O⊡Malley, G., John-Stewart, G. C., & Beima-Sofie, K. M. (2020). Community Perceptions About Use of Pre-exposure Prophylaxis Among Adolescent Girls and Young Women in Kenya. *The Journal of the Association of Nurses in AIDS Care: JANAC, 31*(6), 669–677. https://doi.org/10.1097/JNC.000000000000191
- 46. Bergam, S., Harrison, A. D., Benghu, N., Khumalo, S., Tesfay, N., Exner, T., Miller, L., Dolezal, C., Hanass-Hancock, J., & Hoffman, S. (2022). Women's Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa. *AIDS and Behavior*. https://doi.org/10.1007/s10461-022-03632-6
- 47. Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K., Mangxilana, N., Nobula, L., Bulterys, M. A., Atujuna, M., Hosek, S., Heffron, R., Bekker, L.-G., Mgodi, N., Chirenje, M., Celum, C., Delany-Moretlwe, S., & HPTN 082 study group. (2020). The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. *Journal of the International AIDS Society*, 23(3), e25463. https://doi.org/10.1002/jia2.25463
- 48. Pintye, J., Beima-Sofie, K. M., Makabong'O, P. A., Njoroge, A., Trinidad, S. B., Heffron, R. A., Baeten, J. M., Celum, C., Matemo, D., Kinuthia, J., Kelley, M. C., & John-Stewart, G. C. (2018). HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy. *AIDS Patient Care and STDs*, 32(12), 538–544. https://doi.org/10.1089/apc.2018.0058
- 49. Rousseau, E., Katz, A. W. K., O'Rourke, S., Bekker, L.-G., Delany-Moretlwe, S., Bukusi, E., Travill, D., Omollo, V., Morton, J. F., O'Malley, G., Haberer, J. E., Heffron, R., Johnson, R., Celum, C., Baeten, J. M., & van der Straten, A. (2021). Adolescent girls and young women's PrEP-user journey during an implementation science study in South Africa and Kenya. *PloS One*, 16(10), e0258542. https://doi.org/10.1371/journal.pone.0258542

- 50. Moran, A., Mashele, N., Mvududu, R., Gorbach, P., Bekker, L.-G., Coates, T. J., Myer, L., & Joseph Davey, D. (2022). Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence. *AIDS and Behavior*, *26*(1), 205–217. https://doi.org/10.1007/s10461-021-03374-x
- 51. Mayo, A. J., Browne, E. N., Montgomery, E. T., Torjesen, K., Palanee-Phillips, T., Jeenarain, N., Seyama, L., Woeber, K., Harkoo, I., Reddy, K., Tembo, T., Mutero, P., Tauya, T., Chitukuta, M., Gati Mirembe, B., Soto-Torres, L., Brown, E. R., Baeten, J. M., van der Straten, A., & MTN-020/ASPIRE study team. (2021). Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. *AIDS and Behavior*, 25(8), 2430–2440. https://doi.org/10.1007/s10461-021-03205-z
- 52. Montgomery, E. T., van der Straten, A., Chitukuta, M., Reddy, K., Woeber, K., Atujuna, M., Bekker, L.-G., Etima, J., Nakyanzi, T., Mayo, A. J., Katz, A., Laborde, N., Grossman, C. I., Soto-Torres, L., Palanee-Phillips, T., Baeten, J. M., & MTN-020/ASPIRE Study. (2017). Acceptability and use of a dapivirine vaginal ring in a phase III trial. *AIDS (London, England)*, 31(8), 1159–1167. https://doi.org/10.1097/QAD.000000000001452
- 53. Nel, A., Bekker, L.-G., Bukusi, E., Hellstr⊡m, E., Kotze, P., Louw, C., Martinson, F., Masenga, G., Montgomery, E., Ndaba, N., van der Straten, A., van Niekerk, N., & Woodsong, C. (2016). Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. *PloS One*, 11(3), e0147743. https://doi.org/10.1371/journal.pone.0147743
- 54. van der Straten, A., Ryan, J. H., Reddy, K., Etima, J., Taulo, F., Mutero, P., Taylor, J., Piper, J., Musara, P., & MTN-041/MAMMA Study Team. (2020). Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. *Journal of the International AIDS Society*, 23(6), e25536. https://doi.org/10.1002/jia2.25536
- 55. Minnis, A. M., Browne, E. N., Boeri, M., Agot, K., van der Straten, A., Ahmed, K., Weinrib, R., & Mansfield, C. (2019). Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. *Journal of Acquired Immune Deficiency Syndromes* (1999), 80(4), 394–403. https://doi.org/10.1097/QAI.000000000001945
- 56. van der Straten, A., Agot, K., Ahmed, K., Weinrib, R., Browne, E. N., Manenzhe, K., Owino, F., Schwartz, J., Minnis, A., & TRIO Study Team. (2018). The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. *Journal of the International AIDS Society*, 21(3), e25094. https://doi.org/10.1002/jia2.25094
- 57. Weinrib, R., Minnis, A., Agot, K., Ahmed, K., Owino, F., Manenzhe, K., Cheng, H., & van der Straten, A. (2018). End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa. *AIDS and Behavior*, 22(1), 133–145. https://doi.org/10.1007/s10461-017-1911-6

Table 1: Demographics and health characteristics of pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022 (N=394 women)

	Overall	South Africa	Kenya	<i>p</i> -value
	(N=394, %)	(n=190, %)	(n=204, %)	
Age (median, IQR)	28 [24-32]	27 [22-32]	29 [25-33]	<0.01
Pregnant (n, %)	105 (27)	63 (33)	42 (21)	0.01
Postpartum (n, %)	289 (73)	127 (67)	162 (79)	0.01
Days on oral PrEP (median, IQR)	335 [168-420]	337 [263-420]	308 [114-442]	0.04
Last grade completed (n, %)				
Primary school (Grades 1-6)	28 (7)	2 (1)	26 (13)	<0.01
Some secondary school (Grades 7-11)	236 (60)	106 (56)	130 (64)	
Completed secondary school	90 (23)	70 (37)	20 (9)	
Some tertiary	16 (4)	8 (4)	8 (4)	
Completed tertiary	24 (6)	4 (2)	20 (10)	
Currently employed (formally or informally)? (n, %)				
No	313 (79)	136 (72)	177 (87)	<0.01
Yes	80 (20)	54 (28)	26 (13)	
Prefer not to answer	1 (1)	0 (0)	1 (1)	
Currently have at least one sexual partner (n, %)				
No	21 (5)	15 (8)	6 (3)	0.03
Yes	373 (95)	175 (92)	198 (97)	
HIV Risk Perception $(n, \%)$				
No risk at all	121/380 (32)	84/176 (48)	37 (18)	<0.01
Small chance	145/380 (44)	56/176 (32)	89 (44)	
Moderate chance	89/380 (34)	20/176 (11)	69 (34)	
Great chance	23/380 (6)	16/176 (9)	7 (3)	
Prefer not to answer	2/380(1)	0/176 (0)	2 (1)	
Current alcohol use (n, %)				
Never	363/380 (96)	164/176 (93)	199 (98)	0.31
Monthly or less	11/380 (3)	8/176 (5)	3 (2)	
2-4 times a month	5/380 (1)	3/176 (2)	2 (1)	
2-3 times a week	1/380(1)	1/176 (1)	0 (0)	
4 or more times a week	0 (0)	0 (0)	0 (0)	
HIV PrEP Stigma [‡] (n, %)	. ,	• •	, ,	
Endorsed 0 forms of stigma	251/380 (66)	128/176 (73)	123 (60)	0.01
Endorsed >1 form of stigma	129/380 (34)	48/176 (27)	81 (40)	
Any oral PrEP use over past 30 days (n, %)	,	. , ,	. ,	
No	100 (25)	34 (18)	66 (32)	<0.01
Yes	294 (75)	156 (82)	138 (68)	\0.01
Clinic transportation (n, %)	254 (75)	130 (02)	130 (00)	
Walking	31 (8)	16 (8)	15 (7)	<0.01
_				VU.U1
Taxi/Minibus	206 (52)	172 (91)	34 (17)	
Private car	3 (1)	2 (1)	1 (1)	
Motorbike	152 (38)	0 (0)	152 (75)	
Other	2 (1)	0 (0)	2 (1)	40.04
Total travel time to clinic and return (minutes, median, IQR)	40 [30-60]	30 [20.0-40.0]	55 [31.0-60.0]	<0.01
Cost to travel to clinic and return (USD, median, IQR)	1.32 [1.31-1.74]	1.32 [1.32-1.32]	1.75 [0.88-2.64]	0.02

† Participants were asked "How would you describe your chances of getting HIV in the next year?" with the option to select "No risk at all," "Small chance," "Moderate chance," "Great chance," or "Prefer not to answer."

[‡] Participants were asked to respond on a 5-point Likert scale from "Strongly Disagree" to "Strongly Agree" to 7 statements on potential stigma experienced regarding PrEP use (i.e. "I feel ashamed of using PrEP," "I feel embarrassed about using PrEP").

Have you ever used any of the following family planning methods? (n, %)

Male condom	217 (55)	171 (90)	46 (23)	<0.01
Oral contraceptive pill	98 (25)	42 (22)	56 (27)	0.22
Injectable contraceptive	312 (79)	178 (94)	134 (66)	<0.01
Contraceptive implant	181 (46)	70 (37)	111 (54)	< 0.01
Female condom	8 (2)	6 (3)	2 (1)	0.97
Vaginal contraceptive ring	2 (1)	0 (0)	2 (1)	0.27
IUD/loop	6 (2)	3 (2)	3 (2)	0.69
Other (tubal ligation)	2 (1)	0 (0)	2 (1)	0.27
None	11 (3)	1 (1)	9 (4)	0.01

Table 2: Likes and dislikes regarding daily oral PrEP in pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022


Oral PrEP likes	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	<i>p</i> -value
HIV prevention	386 (98)	186 (98)	200 (98)	0.92
PrEP has few/no side effects	61 (15)	35 (18)	26 (13)	0.12
Ease of use	27 (7)	16 (8)	11 (5)	0.23
No interruption of sex (as is needed for condoms)	16 (4)	5 (3)	11 (5)	0.17
Easy to hide	10 (3)	0 (0)	10 (5)	<0.01
Take it daily	8 (2)	5 (3)	3 (2)	0.88
Taken orally	7 (2)	5 (3)	2 (1)	0.95
PrEP is safe for the baby	5 (1)	5 (3)	0 (0)	0.03
Other (e.g., overall safety, increased appetite, peaceful sleep)	4 (1)	4 (2)	0 (0)	0.05
Nothing	1 (1)	0 (0)	1 (1)	0.52


Oral PrEP dislikes	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	<i>p</i> -value
Side effects	100 (25)	39 (21)	61 (30)	0.03
Must take it daily	90 (23)	38 (20)	52 (25)	0.20
Must take orally	35 (9)	12 (6)	23 (11)	0.08
Pill size is too big	12 (3)	9 (5)	3 (2)	0.99
No STI prevention	10 (3)	4 (2)	6 (3)	0.42
Not discreet	9 (2)	0 (0)	9 (4)	<0.01
Other (e.g., general dislike, pill taste, pill smell)	3 (1)	2 (1)	1 (1)	0.90
Nothing	201 (51)	111 (58)	90 (44)	<0.01

Table 3: Ranked characteristics of potential HIV prevention products among pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022

Most important characteristic of a potential HIV prevention product (ranked #1)	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	<i>p</i> -value
Effective at preventing HIV	203 (52)	44 (23)	159 (78)	<0.01
Healthy pregnancy	47 (12)	36 (19)	11 (5)	<0.01
How frequently it is used (e.g. before sex, once a day, once a month)	39 (10)	35 (18)	4 (2)	<0.01
Side effects	39 (10)	31 (16)	8 (4)	<0.01
Ability to breastfeed and have healthy baby	26 (7)	15 (8)	11 (5)	0.32
How it is used (e.g. vaginal ring, injected, pill)	25 (6)	16 (8)	9 (4)	0.10
Privacy (from partner)	13 (3)	11 (6)	2 (1)	0.01
Other (not forgotten easily, overall safety)	2 (1)	2 (1)	0 (0)	0.23
Most important access-related characteristic of a potential HIV prevention product (ranked #1)				
Free of charge	203 (52)	104 (55)	99 (49)	0.22
How easy it is to obtain	79 (20)	43 (23)	36 (18)	0.22
Where to pick up (clinic, pharmacy, community)	48 (12)	28 (15)	20 (10)	0.14
Total time it takes to get product	31 (8)	15 (8)	16 (8)	0.99
Most preferable frequency of HIV prevention method (ranked #1)				
Before sex	53 (13)	30 (16)	23 (11)	0.19
After sex	6 (2)	5 (3)	1 (1)	0.10
Every day	46 (12)	26 (14)	20 (10)	0.23
Once per month	62 (16)	25 (13)	37 (18)	0.18
Once every 2-3 months	59 (15)	17 (9)	42 (21)	<0.01
Once every 6 months	45 (11)	11 (6)	34 (17)	<0.01
Once yearly	123 (31)	76 (40)	47 (23)	<0.01

Figure 1: Theoretical acceptability of long-acting PrEP methods versus daily oral PrEP by pregnant and postpartum women with experience taking oral PrEP, Kenya and South Africa, September 2021 – February 2022 (N=394 women)





medRxiv preprint doi: https://doi.org/10.1101/2022.10.29.22281701; this version posted October 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 4: Factors associated with of long-acting PrEP preference vs. oral PrEP among pregnant and postpartum women with experience taking oral PrEP, N=394

	Summary Statistics					
	Wants long-acting (n=305, %)	Wants oral PrEP (n=89, %)	Unadjusted OR (95% CI)	<i>p</i> -value	Adjusted OR [†] (95% CI)	<i>p</i> -value
Maternal age (median, IQR) years	28 [24-32]	27 [23-31]	1.03 [0.99-1.08]	0.11	1.04 [0.99, 1.08]	0.11
≥25 years	221 (72)	59 (66)	1.34 [0.81-2.22]	0.26	1.35 [0.81-2.27]	0.25
<25 years	84 (28)	30 (34)				
Country						
Kenya	158 (52)	46 (52)	1.01 [0.63-1.61]	0.98	0.93 [0.57, 1.51]	0.77
South Africa	147 (48)	43 (48)				
Pregnancy status						
Pregnant	78 (26)	27 (30)	0.79 [0.47-1.33]	0.37	0.82 [0.48, 1.39]	0.46
Postpartum	227 (74)	62 (70)	- ·		- · ·	
Time on PrEP (median, IQR) days	331 [168-422]	336 [185-420]	1.00 [1.00-1.00]	0.90	1.00 [1.00-1.00]	0.78
Last grade completed (ref: primary school)	27 (9)	10 (11)	ref	ref	ref	ref
Some secondary	178 (58)	64 (72)	1.20 [0.55-2.64]	0.64	1.12 [0.52, 2.74]	0.67
Completed secondary	72 (24)	17 (19)	1.48 [0.61-3.61]	0.39	1.62 [0.61, 4.32]	0.34
Some or all tertiary	20 (7)	3 (3)	1.78 [0.53-5.94]	0.35	1.68 [0.49, 5.79]	0.41
Currently employed (formally or informally)						
Employed	61/304 (20)	19 (21)	0.93 [0.52-1.65]	0.79	0.81 [0.44-1.49]	0.49
Not employed	243/304 (80)	70 (79)				
At least one sexual partner						
≥1 sexua partner	288 (94)	85 (96)	0.80 [0.26-2.43]	0.69	0.75 [0.24-2.30]	0.61
O sexual partners	16 (5)	4 (4)				
PrEP stigma (median, IQR)	14 [13-17]	15 [13-16]	1.02 [0.96-1.09]	0.56	1.03 [0.96-1.10]	0.45
Endorsed 0 stigma	193/293 (66)	58/87 (67)	1.03 [0.62-1.72]	0.89	1.06 [0.63-1.77]	0.83
Endorsed ≥1 stigma statement	100/293 (34)	29/87 (33)				
HIV Risk Perception						
Any perceived HIV risk	194/291 (67)	63/87 (72)	0.76 [0.45, 1.29]	0.31	0.75 [0.43, 1.31]	0.31
No perceived HIV risk	97/291 (33)	24/87 (28)				
Alcohol use						
Endorses any alcohol use	12/293 (4)	5/87 (6)	0.70 [0.24-2.05]	0.52	0.73 [0.25-2.17]	0.58
Does not endorse alcohol use	281/293 (96)	82/87 (94)				
PrEP persistence (has the participant taken PrEP						
over the past 30 days?)						
Yes	222 (73)	72 (81)	0.63 [0.35-1.13]	0.12	0.65 [0.36, 1.19]	0.16
No	83 (27)	17 (19)				
Time traveled to clinic and return (median, IQR)	40 [30-60]	40 [30-60]	1.00 [0.99-1.01]	0.95	0.99 [0.99-1.01]	0.99

minutes						
Cost to travel to clinic and return (median, IQR) USD equivalent	1.29 [1.29-1.71]	1.29 [1.29-1.71]	1.12 [0.86-1.45]	0.40	1.11 [0.85-1.45]	0.44
Contraceptive used in the past						
Injection	252 (83)	60 (67)	2.30 [1.35-3.92]	0.002	2.48 [1.34, 4.57]	<0.01
Condom	172 (56)	45 (51)	1.26 [0.79-2.03]	0.33	1.59 [0.82, 3.07]	0.17
Condom	172 (50)	45 (51)	1.20 [0.75 2.05]	0.55	1.55 [0.02, 5.07]	0.17
Implant	134 (44)	47 (53)	0.70 [0.44-1.12]	0.14	0.71 [0.44, 1.16]	0.17
Oral contraceptive	79 (26)	19 (21)	1.29 [0.73-2.27]	0.38	1.22 [0.69-2.17]	0.50
Female condom	4 (1)	4 (4)	0.28 [0.07-1.15]	0.08	0.27 [0.07-1.12]	0.07
Vaginal ring	1 (0.3)	1 (0.3)	0.29 [0.02-4.68]	0.38	0.27 [0.02-4.42]	0.36
Oral PrEP likes						
HIV prevention	298 (98)	87 (98)	0.98 [0.20-4.80]	0.98	0.95 [0.19-4.66]	0.95
No side effects	50 (16)	11 (12)	1.39 [0.69-2.80]	0.36	1.43 [0.71-2.90]	0.32
Ease of use	21 (7)	6 (7)	1.02 [0.40-2.62]	0.96	1.07 [0.41-2.75]	0.90
No interruption of sex	12 (4)	4 (4)	0.87 [0.27-2.77]	0.81	0.87 [0.27-2.80]	0.82
Easy to hide	7 (2)	3 (3)	0.67 [0.17-2.66]	0.57	0.63 [0.16-2.56]	0.52
Take it daily	4 (1)	4 (4)	0.28 [0.07-1.15]	0.08	0.30 [0.07-1.24]	0.10
Take it orally	4(1)	3 (3)	0.38 [0.08-1.73]	0.21	0.38 [0.08-1.77]	0.22
Nothing	1 (0.3)	o (o)				
Oral PrEP dislikes	, ,	` '				
Dislikes at least one thing about oral PrEP	158 (52)	35 (39)	1.66 [1.03-2.68]	0.04	1.72 [1.05, 2.80]	0.03
Side effects	81 (27)	18 (20)	1.43 [0.80-2.54]	0.23	1.43 [0.80, 2.55]	0.23
Daily use	75 (25)	13 (15)	1.91 [1.00-3.63]	0.05	1.92 [1.01, 3.67]	0.05
Take it orally	28 (9)	7 (8)	1.18 [0.50-2.81]	0.70	1.20 [0.50, 2.85]	0.69
Not discreet	7 (2)	2 (2)	1.02 [0.21-5.01]	0.98	1.09 [0.22, 5.46]	0.92
No STI protection	6 (2)	4 (4)	0.43 [0.12-1.55]	0.20	0.45 [0.12, 1.64]	0.23
Preferred frequency of PrEP use						
Ranked every month, 2-3 months, 6	230 (75)	59 (66)	1.56 [0.94-2.60]	0.09	1.58 [0.94, 2.65]	0.08
months, or year #1						
Ranked before sex, after sex, or every day #1	75 (25)	30 (34)				
Interested in community PrEP delivery						
Yes	131 (43)	32 (36)	1.34 [0.82-2.19]	0.24	1.45 [0.85, 2.45]	0.17
No	174 (57)	57 (64)				
[†] Each individual model adjusted for maternal ago	e, country					

Bold *p*<0.10

Supplementary Table 1: Reasons behind preference of long-acting PrEP methods versus oral PrEP methods by pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya

If injectable PrEP was approved as safe for pregnant women to use, would you prefer to keep using oral PrEP or switch to	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	<i>p</i> -value
the injection?	•		·	
Keep using oral PrEP	94 (24)	48 (25)	46 (23)	0.53
Switch to injectable PrEP	297 (75)	141 (74)	156 (76)	0.60
Unsure	3 (0.8)	1 (0.5)	2 (1)	0.53
For those who selected injectable PrEP over oral PrEP: What				
characteristics about the injection make you interested in	Overall	South Africa	Kenya	<i>p</i> -value
switching?	(n=297)	(n=141)	(n=156)	
Longer duration/once every 8 weeks	188 (63)	123 (87)	65 (42)	<0.01
Not having to remember to take a pill every day	144 (48)	80 (57)	64 (41)	<0.01
Easy to keep private from my partner/others	83 (28)	7 (5)	76 (49)	<0.01
Administered by medical professional	40 (13)	9 (6)	31 (20)	< 0.01
Not carrying pills	83 (28)	18 (13)	65 (42)	<0.01
Other (e.g., fewer potential side effects, comfort with contraceptive injection)	5 (2)	5 (4)	0 (0)	0.02
For those who selected "Oral PrEP" or "Unsure": What				
characteristics about the injection make you not interested or	Overall	South Africa	Kenya	<i>p</i> -value
unsure about switching?	(n=97)	(n=49)	(n=48)	
Injection pain	71 (73)	37 (76)	34 (71)	0.60
Potential side effects	24 (25)	15 (31)	9 (19)	0.18
Not enough safety data (i.e. afraid of impact on me)	13 (13)	2 (4)	11 (23)	<0.01
Worry about impact on baby's health after delivery due to being on PrEP while breastfeeding	6 (6)	0 (0)	6 (13)	0.01
Worry about impact on having a healthy pregnancy due to PrEP	3 (3)	0 (0)	3 (6)	0.12
Once every 8 weeks	1(1)	0 (0)	1 (2)	0.50
Other (e.g., needle fears, does not want more clinic, mistrust	5 (5)	5 (10)	0 (0)	0.03
of contraceptive injection, used to oral PrEP)				
If the vaginal ring was approved as safe for pregnant or				
breastfeeding women to use, would you prefer to keep using		0 1 661		
oral PrEP or switch to the vaginal ring?	Overall	South Africa	Kenya	מוולבע מ
	(N=394)	(n=190)	(n=204)	<i>p</i> -value
Keep using oral PrEP	(N=394) 344 (87)	(n=190) 165 (87)	-	0.79
			(n=204)	-
	344 (87)	165 (87)	(n=204) 179 (88)	0.79
Switch to vaginal ring	344 (87) 40 (10)	165 (87) 22 (12)	(n=204) 179 (88) 18 (9)	0.79 0.37
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP:	344 (87) 40 (10)	165 (87) 22 (12) 3 (2)	(n=204) 179 (88) 18 (9) 7 (3)	0.79 0.37 0.20
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in	344 (87) 40 (10) 10 (3)	165 (87) 22 (12)	(n=204) 179 (88) 18 (9)	0.79 0.37 0.20
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching?	344 (87) 40 (10) 10 (3) Overall	165 (87) 22 (12) 3 (2) South Africa	(n=204) 179 (88) 18 (9) 7 (3) Kenya	0.79 0.37 0.20
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in	344 (87) 40 (10) 10 (3) Overall (n=40)	165 (87) 22 (12) 3 (2) South Africa (n=22)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18)	0.79 0.37 0.20 <i>p</i> -value
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17)	0.79 0.37 0.20 p-value
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28)	0.79 0.37 0.20 p-value <0.01 0.09
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 17 (43)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44)	0.79 0.37 0.20 p-value <0.01 0.09 0.82
For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 3 (8) 2 (5)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom)	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 3 (8) 2 (5) 2 (5)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08 1 0.30
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 2 (5) 2 (5)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) South Africa	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching?	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 3 (8) 2 (5) 2 (5) (5) Overall (n=354)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) 2 (9) South Africa (n=168)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 0.08 1 0.30 p-value
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching? Insertion into vagina	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 3 (8) 2 (5) 2 (5) Overall (n=354) 228 (64)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) 2 (9) South Africa (n=168) 138 (82)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186) 90 (48)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 1 0.30 p-value <0.01
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching? Insertion into vagina Side effects	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 2 (5) 2 (5) Overall (n=354) 228 (64) 97 (27)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) 2 (9) South Africa (n=168) 138 (82) 36 (21)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186) 90 (48) 61 (33)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 1 0.30 p-value <0.01 0.02
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching? Insertion into vagina Side effects Not enough safety data (i.e. afraid of impact on me)	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 2 (5) 2 (5) Overall (n=354) 228 (64) 97 (27) 89 (25)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) South Africa (n=168) 138 (82) 36 (21) 39 (23)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186) 90 (48) 61 (33) 50 (27)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 1 0.30 p-value <0.01 0.02 0.43
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching? Insertion into vagina Side effects Not enough safety data (i.e. afraid of impact on me) User or partner may feel it	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 17 (43) 3 (8) 3 (8) 2 (5) 2 (5) Overall (n=354) 228 (64) 97 (27) 89 (25) 51 (14)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) South Africa (n=168) 138 (82) 36 (21) 39 (23) 13 (8)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186) 90 (48) 61 (33) 50 (27) 38 (20)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 1 0.30 p-value <0.01 0.02 0.43 <0.01
Switch to vaginal ring Unsure For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching? Longer duration/once a month Not having to remember to take a pill every day Easy to use Not carrying pills Unable to feel it Easy to keep private from my partner/others Fewer side effects Other (familiarity with contraceptive ring/internal condom) For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching? Insertion into vagina Side effects Not enough safety data (i.e. afraid of impact on me)	344 (87) 40 (10) 10 (3) Overall (n=40) 17 (43) 17 (43) 7 (18) 3 (8) 2 (5) 2 (5) Overall (n=354) 228 (64) 97 (27) 89 (25)	165 (87) 22 (12) 3 (2) South Africa (n=22) 14 (64) 12 (55) 9 (41) 1 (5) 0 (0) 0 (0) 2 (9) 2 (9) South Africa (n=168) 138 (82) 36 (21) 39 (23)	(n=204) 179 (88) 18 (9) 7 (3) Kenya (n=18) 3 (17) 5 (28) 8 (44) 6 (33) 3 (17) 3 (17) 0 (0) 0 (0) Kenya (n=186) 90 (48) 61 (33) 50 (27)	0.79 0.37 0.20 p-value <0.01 0.09 0.82 0.02 0.08 1 0.30 p-value <0.01 0.02 0.43

Worry about impact on baby's health after delivery due to	28 (8)	6 (4)	22 (12)	<0.01
being on PrEP while breastfeeding				
Once a month	15 (4)	3 (2)	12 (7)	0.03
Other (e.g. reduced risk/discomfort with incorrect usage, comfort with pills, fear that ring is scented, general discomfort/mistrust, ashamed)	14 (4)	11 (7)	3 (2)	0.02